PharmaCielo Ltd. cultivates and supplies medicinal-grade cannabis extracts in Canada. The company faces significant financial challenges, evidenced by a low financial health score of 16/100, negative EBITDA and net margins, and a concerning current ratio of 0.14, indicating liquidity issues. While it has a gross margin of 37.3%, the overall financial performance raises concerns about sustainability and growth potential. The stock's current price of $0.05 reflects market skepticism, especially after a 9.09% decline today.
Loading financial metrics...
Company has $77K in cash but burned $1.7M last quarter. At this burn rate, only 0.0 quarters of runway remain without additional financing.
Revenue fell 17.6% year-over-year from $4.4M to $3.6M. The decline has persisted for multiple quarters.
Company posted a loss of $-3.7M over the last year, representing 103.1% of revenue.
Debt of $18.2M is 235.0x the company's cash position of $77K.
No significant opportunities identified
Based on current financial metrics
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2027-Q1 (June 30, 2026)